#USA #New York #cancer therapy #Actinium Pharmaceuticals #ATNM-400

Actinium Pharmaceuticals Presents ATNM-400 at EANM 2026

On October 16, 2026, Actinium Pharmaceuticals, Inc., a leader in targeted radiotherapy for cancer, made a significant announcement regarding their innovative drug, ATNM-400. This announcement arrives as the company prepares to present its findings at the 39th Annual Congress of the European Association of Nuclear Medicine (EANM) in Vienna, Austria, from October 17-21, 2026.

Key Highlights from the Presentation

Actinium's presentation features valuable preclinical data demonstrating ATNM-400's antitumor capabilities across several challenging cancer types, including non-small cell lung cancer (NSCLC), colorectal cancer, and ovarian cancer models. Notably, ATNM-400, which utilizes Actinium-225 (²²⁵Ac) technology, has shown promise not only as a sole treatment but also as an enhancer when combined with established therapies.

NSCLC Findings

In studies centered on NSCLC, ATNM-400 exhibited robust antitumor activity. Specifically, it showed substantial effects as both a standalone solution and in synergy with KRAS and ALK inhibitors, even in drug-resistant scenarios. This builds on prior promising results seen with EGFR mutations, underscoring ATNM-400's potential as a mutation-agnostic treatment option.

Colorectal Cancer Insights

Colorectal cancer models further validated ATNM-400's potency, revealing significant responses when tested alone as well as in combination with common therapies such as bevacizumab and oxaliplatin. This suggests that ATNM-400 may substantially improve treatment outcomes, particularly in patients who are typically less responsive to conventional care.

Ovarian Cancer Advancements

The ovarian cancer findings stood out as well, indicating ATNM-400's ability to provoke durable antitumor responses even in types that have previously resisted other treatments. This positions ATNM-400 as a potentially groundbreaking option for patients facing recurrent ovarian cancer, particularly in cases involving prior treatment failures.

Executive Insights

Sandesh Seth, Actinium's Chairman and CEO, expressed optimism about the breadth of ATNM-400's therapeutic application across various solid tumors. He highlighted the high incidence of NSCLC and the encouraging data from both colorectal and tough-to-treat ovarian cancer models as pivotal in the company's vision to expand targeted radiotherapy applications.

Conclusion

With an expansive pipeline focused on innovative radiotherapies, including ATNM-400, Actinium Pharmaceuticals is poised to significantly alter the treatment landscape for cancer patients. The forthcoming presentations at EANM 2026 will not only showcase the potential of ATNM-400 but also reinforce the company's commitment to addressing significant unmet needs within oncology.

For more information, visit Actinium's official website.

Future Directions

As the landscape of cancer therapy continues to evolve, Actinium is committed to driving breakthroughs that maximize patient outcomes and minimize adverse effects. Their ongoing research and clinical efforts aim to establish ATNM-400 as a mainstay in oncology treatment regimens.

With promising findings on the horizon, the oncology community eagerly anticipates the insights that will emerge from the EANM 2026 congress.